L&89 A5574;*)	10/14/2023	O<3*7	J&3* M(H4<&9: F" 12 M4 F&(:19>
N*=9 *;.*<	10/13/2026	D4(: 2*39 A7*&	! OM- O7, &3.?&9.43&1 D4(: 2*398
		A551.(&' .1.9>	! &.39 L4: .8 #3.; *78.9>

Continuing Medical Education Committee Charter

Mission Statement/Purpose

" – * C439.3: .3, M*).(&1 E): (&9.43 (CME) C422.99** <.11 &);.8* 9–* CME A((7*).9.3, D.7*(947 &3) 9–* CME P74, 7&2 D.7*(947 7*, &7).3, 541.(.*8 &3) .88:*8 &++*(9.3, 9–* , *3*7&1 45*7&9.43 4+ 9–* 4;*7&11 (439.3: .3, 2*).(&1 *): (&9.43 574, 7&2.

Membership

$49.3, 2*2' *78 4+ 9–* CME C422.99** &7* &554.39*) ' >a

(*39 (50%) 4+ 9–* 2**9.3, 8 +4

% '   2*2' *78 <.11 .3(1:)* 9-* CME A((7*).9.3, D.7*(947, CME B: 8.3*88 D.7*(947, CME P74, 7&2 D.7*(947 &3) CME P74, 7&2 C447).3&947.

Chair

M&7.* P-.1.53*7., M.D., P-.D., CME A((7*).9.3, D.7*(947 (C4-C-&.7)

A2&3)& ! &.3, CME P74, 7&2 D.7*(947 (C4-C-&.7)

Responsibilities

" -* CME C422.99** <.11 &) ;.8* &3) 2&0* 7*(422*3)&9.438 7*, &7).3, 541.(.*8 +47 9-* 45*7&9.43 4+ CME 574, 7&28 .3 (4251.&3(* <.9- 9-* E88*39.&1 A7*&8 &3) P41.(.*8 4+ 9-* A((7*).9&9.43 C4: 3(.1 +47 C439.3: .3, M*).(&1 E): (&9.43 (ACCCME) &3) 9-* ! 9&3) &7)8 +47 I39*, 7.9> &3) I3)*5*3)*3(* .3 A((7*).9*) C439.3: .3, E): (&9.43.

" -* C422.99** <.11).8(: 88 9-* 2.88.43 89&9*2*39 *; *7> 9<4 >*&78 94 *38: 7* 9-* CME P74, 7&2 .8 2**9.3, 9-* , 4&18 4+ 9-* 2.88.43.

" -* CME C422.99** <.11 7*;.*< 9-* *; &1: &9.43 4+ 9-* 4; *7&11 CME 574, 7&2 &9 7*, : 1&71> 8(-*): 1*) &0*74&18, 9-* *++*(9.; *3*88 4+ 9-* &) 2.3.897&9.; &85*(98 4+ 9-* CME OA(* 47 P74, 7&2 &3) 4: 91.3* 9-* 897&9*, . (51&3 +47 9-* 574, 7&2.

<div>AME P7,
",384)*7</div>

O9-*7 &7*&8 4+).8(: 88.43 2&> .3(1:)* /4.39 574;.)*7 7*;.*< 94)*9*72.3* .+ 9-* /4.39 574;.)*78 2.88.43 +&118 .3 1.3* <.9- 9--&9 4+ 9-* ! (-441 4+ M*).(.3*, (4251.&3(* .88: *8 <.9- &)*)5&792*39 47 /4.39 574;.)*78 47, &3) .9*28 +47 9-* CME P74, 7&2 <*' 8.9*.

Meetings/Procedures

" -* (422.99** 2*2' *78 8-&11 2**9.3 5*7843, 47 ;.79: &11>, *; *7> 6: &79*7. ! 5*(.&1 2**9.3, 8 2&>' * (&11*) ' > 9-* C422.99** C-&.7. #7, *39 945.(8 47 .88: *8 (&3 ' * 7*6: *89*) +74 9-* CME P74, 7&2 D.7*(947 47 9-* (422.99** 2*2' *78. #7, *39 945.(8 47 .88: *8 <.11 ' * 7*;.*<*) ' > 9-* C422.99** C-&.7 94)*9*72.3* .+ & 85*(.&1 2**9.3, .8 &557457.&9*7 47 .+ 9-* 2&99*7 (&3 <&.9 : 39.1 9-* 3*=9 8(-*): 1*) 2**9.3, .

" -* 47

M.3: 9*8 <.11 ' * 7*(47)*) ' > 9-* CME P74, 7&2 C447).3&947 &3)).897.' : 9*) 94 9-* CME C422.99**
2*2' *78 <.9-.3 43* 2439- 4+ *&(- 2**9.3, 4((: 77*3(*.

History

! & !

& !! " ! ! $! ! ! # &

& !!

A5574; &1 ! ., 3&9: 7*8

Step Description	Approver	Date
$P M*).(&1 A++&.78	C-7.89.3* J&(4' 8: N43*	10/14/2023
! OM 4+ P41.(> &3) P74(*): 7* *;.*< C422.99**	! 9*5-&3.* D*(0*7	10/14/2023
! OM 4+ P41.(> &3) P74(*): 7* *;.*< C422.99**	J&3* M(H4<&9: F" 12 M4 F&(: 19>	10/13/2023

A551.(&' .1.9>

! &.39 L4: .8 #3.; *78.9>